MeiraGTx receives FDA breakthrough therapy designation for xerostomia treatment

March 26, 2026 8:00 AM

MeiraGTx Holdings plc (NASDAQ: MGTX) announced that the FDA granted Breakthrough Therapy Designation for its AAV2-hAQP1 treatment for Grade 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found